American Portfolios Advisors’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

American Portfolios Advisors’s Portfolio GNRX Stock Details GNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,419	Closed	-$142K	–	2818
2019 Q1	$142K	Hold	6,419	–	–	0.01%	746
2018 Q4	$133K	Hold	6,419	–	–	0.02%	645
2018 Q3	$163K	Sell	6,419 -450	-7%	-$11.4K	0.02%	660
2018 Q2	$172K	Sell	6,869 -362	-5%	-$8.92K	0.02%	611
2018 Q1	$177K	Sell	7,231 -80	-1%	-$2.01K	0.03%	563
2017 Q4	$178K	Buy	+7,311	New	+$170K	0.03%	541

American Portfolios Advisors's GNRX Position: Q2 2019 in Review

American Portfolios Advisors sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q2 2019, closing a stake of 6,419 shares — an estimated $142K sold.

American Portfolios Advisors first reported a position in GNRX in Q4 2017 and held it in 6 quarters. The position peaked at $178K in Q4 2017. 0 funds tracked by Wall St. Rank hold GNRX as of Q2 2019.

American Portfolios Advisors reported no remaining VanEck Vectors Generic Drugs ETF position as of Q2 2019 after selling out during the quarter.
American Portfolios Advisors sold 6,419 VanEck Vectors Generic Drugs ETF shares in Q2 2019, an estimated $142K.
American Portfolios Advisors first reported a position in VanEck Vectors Generic Drugs ETF in Q4 2017 and held it in 6 quarters.
American Portfolios Advisors's VanEck Vectors Generic Drugs ETF position peaked at $178K in Q4 2017.
0 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q2 2019.

Based on American Portfolios Advisors's 13F filing for Q2 2019, filed 24 Mar 2023.